GlobeNewsWire
06 Dec 2025, 19:00 UTC · 49w ago
Legend Biotech Highlights New CARVYKTI® Data in Multiple Myeloma and First-in-Human Results from Novel CAR-T Platform in Non-Hodgkin Lymphoma at ASH 2025
Verdict
Headline takes no side. We score LEGN +1.00 — strongly bullish.
- Expected · LEGN
+1.00strongly bullish
−1 bearish0bullish +1More positive than 99% of ticker scores this week





